Effectiveness of Rapid Intake into Methadone Treatment: A Natural Experiment in Israel

Lawental, Maayan

doi:10.1159/000375491

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A minimum age requirement (usually 18) was mentioned for 6. Other treatment entry criteria included prior attempts at non‐pharmacological treatment for OUD (Armenia and Kyrgyzstan) [18,20], an “unsuccessful” detoxification attempt (Finland [21] and Iran) or evidence of recent use by an opioid positive urine test (Israel, Macao, Tanzania). Requirements for people to have completed detention in a compulsory detoxification centre before OAT entry were removed in China in 2006 [22].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Global opioid agonist treatment: a review of clinical practices by country

Jin

Marshall

Degenhardt³

et al. 2020

Addiction

View full text Add to dashboard Cite

Aims We assessed how opioid agonist treatment (OAT) for opioid use disorder (OUD), specifically methadone and buprenorphine, including buprenorphine‐naloxone, is delivered in routine clinical practice, with a focus on factors that affect access to and delivery of these services. The aims of this review were to summarize eligibility criteria for entry to OAT, doses in routine clinical practice, access to and eligibility for unsupervised dosing and urine drug screening practices in OAT programs globally. Methods We completed searches of PubMed, Embase, and grey literature databases for cross‐sectional or observational cohort studies of OAT using either methadone or buprenorphine. Dose data extracted from eligible studies were compared with guidelines provided by WHO. Results We found 140 reports from 41 countries that contained data for at least one of the relevant indicators. A diagnosis of opioid dependence or opioid use disorder was the most common eligibility requirement for OAT (13 or 17 countries). Reported mean or median doses for methadone ranged from 16–131 mg whereas range for buprenorphine was 2.5–19 mg. Access to unsupervised dosing under some conditions was reported in 18 of 27 countries. Frequency of regular urine drug screenings (UDS) ranged from several times a week to eight times per year (methadone) or as clinically indicated. Conclusions Opioid agonist treatment practices, including doses prescribed, vary greatly both within and across countries. Of particular concern is the persistence of lower dose prescribing practices, in which patients may be prescribed doses below those proven to yield significant clinical benefits.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The frequency of UDS varied from several times a week (e.g. some reports from Israel [18,20]; one report from the United States [21]) to once a month (e.g. patients receiving buprenorphine after stabilisation in some US settings [22]), while others stated that UDS was undertaken as clinically indicated.…”

Section: Resultsmentioning

confidence: 99%